TRIL
$12.65
Trillium Therapeutic
$.35
2.85%
TRIL
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.14)
Revenue:  $0.00 Mil
Thursday
Nov 12
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when TRIL reports earnings?
Beat
Meet
Miss

Where is TRIL's stock price going from here?
Up
Flat
Down
Stock chart of TRIL
Analysts
Summary of analysts' recommendations for TRIL
Score
Grade
Pivots
Resistance
$13.37
$13.02
$12.84

$12.49

Support
$12.31
$11.96
$11.78
Tweet
Growth
Description
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company's lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (do not eat) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (eat) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties.